What is the prevalence of lichen planus in the general population, including oral lichen planus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lichen Planus Prevalence

The global prevalence of oral lichen planus is approximately 0.89-1.01% in the general population, with higher rates (1.43-1.68%) in Europe and lower rates (0.49-0.57%) in Asia, predominantly affecting women over 40 years of age.

Population-Based Prevalence Data

The most robust epidemiological evidence comes from recent systematic reviews and meta-analyses examining oral lichen planus (OLP) specifically, as cutaneous lichen planus data is more limited in the provided evidence.

Overall Prevalence

  • General population: 0.89% (95% CI, 0.38%-2.05%) 1
  • Clinical patients: 0.98% (95% CI, 0.67%-1.43%) 1
  • Alternative estimate: 1.01% globally 2

The most methodologically sound single population study reported an age-standardized prevalence of 1.27% overall (0.96% in men, 1.57% in women) 3. A Swedish population study found 1.9% prevalence (1.6% in men, 2.2% in women) 4.

Geographic Variation

Population-based studies 1:

  • Asia: 0.57% (95% CI, 0.15%-2.18%)
  • Europe: 1.68% (95% CI, 1.09%-2.58%)
  • South America: 1.39% (95% CI, 0.58%-3.28%)

Clinic-based studies 1:

  • Africa: 1.43% (95% CI, 1.12%-1.83%)
  • Asia: 0.87% (95% CI, 0.61%-1.25%)
  • Europe: 1.03% (95% CI, 0.51%-2.09%)
  • North America: 0.11% (95% CI, 0.07%-0.16%)
  • South America: 3.18% (95% CI, 0.97%-9.95%)

The lower prevalence in India (0.49%) may reflect diagnostic masking by tobacco-associated keratosis 2.

Demographic Patterns

Sex Distribution

Women are consistently more affected than men, with pooled prevalence of:

  • Population-based: 1.55% in women vs. 1.11% in men 1
  • Clinic-based: 1.69% in women vs. 1.09% in men 1

Age Distribution

Prevalence increases significantly after age 40 (OR = 3.43,95% CI = 2.48-4.73, p < .001) 2:

  • Under 40 years: 0.62% (95% CI, 0.33%-1.13%)
  • 40 years and older: 1.90% (95% CI, 1.16%-3.10%)

Peak prevalence occurs in the 55-74 age range 4, with bimodal distribution in prepubertal and postmenopausal women for genital lichen sclerosus 5.

Clinical Presentation Patterns

Oral Lichen Planus Characteristics

  • Reticular form: Most common (54.1-77.3%) 4, 6
  • Most affected site: Buccal mucosa (92-44.1%) 4, 6
  • Symptomatic patients: 60-87% report symptoms 6
  • Skin involvement: Only 5.4% have concurrent cutaneous lesions 6

Cutaneous Lichen Planus

The prevalence of cutaneous lichen planus in oral lichen planus patients is extremely low at 0.06% 7, indicating these are largely separate presentations despite being the same disease entity.

Important Clinical Caveats

Diagnostic Considerations

Specialist expertise significantly impacts reported prevalence 2:

  • Oral medicine/pathology specialists: 1.80%
  • General dentists: 0.61%
  • Dermatologists: 0.33%

This suggests substantial underdiagnosis in non-specialist settings, meaning true prevalence may be higher than reported.

Malignant Transformation Risk

While not the primary question, this is critical for quality of life: malignant transformation occurs in approximately 1.43% of OLP cases, increasing to 5.13% when dysplasia is present 8, necessitating long-term surveillance.

Methodological Limitations

Most prevalence studies have significant methodological deficiencies 3. The high heterogeneity (I² statistics not provided but noted as "high" 1) means these estimates should be interpreted cautiously. Studies using defined diagnostic criteria report higher prevalence (1.31% vs. 0.70%, p = .03) 2, suggesting many cases go unrecognized without systematic diagnostic approaches.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.